On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...

Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...

GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...

UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...

GSK (NYSE:GSK) said a Phase 3 study of its drug linerixibat in the treatment of relentless itching in patients with primary ...

Researchers from the National Institutes of Health (NIH) are applying artificial intelligence to the recruitment of ...

The European stock markets closed lower in Tuesday trading as The Stoxx Europe fell 0.43%, Germany's DAX was down 0.67%, the FTSE in London was off 0.13%, France's CAC dropped 0.67%, and the Swiss ...

GSK’s linerixibat helped reduce itch in patients with a rare bile duct disease, meeting its primary endpoint in a late-stage ...

The attack came just days after President Biden gave Ukraine permission to use the weapons to strike targets inside Russia. By Marc Santora and Eric Schmitt The envoy, Amos Hochstein, said an ...

Covering Netflix News Independently Since 2013. What’s on Netflix is not owned by or affiliated with Netflix or any of its partners in any capacity. The authors of this site also have no affiliation ...